HMGB1 regulates IL-33 expression in acute respiratory distress syndrome-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HMGB1 regulates IL-33 expression in acute respiratory distress syndrome

Published:2016-09 Issue: Volume:38 Page:267-274
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Fu Juan,Lin Shi-hui,Wang Chuan-jiang,Li Sheng-yuan,Feng Xuan-yun,Liu Qiong,Xu Fang

Funder

National Natural Science Foundation grants of China

Natural Science Foundation of Chongqing Science and Technology Commission

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference45 articles.

1. Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The consensus committee[J];Bernard;Intensive Care Med.,1994

2. The acute respiratory distress syndrome[J];Ware;N. Engl. J. Med.,2000

3. Has mortality from acute respiratory distress syndrome decreased over time?: a systematic review[J];Phua;Am. J. Respir. Crit. Care Med.,2009

4. Mortality rates for patients with acute lung injury/ARDS have decreased over time[J];Zambon;Chest,2008

5. Multivalent DNA-binding properties of the HMG-1 proteins[J];Maher;Proc. Natl. Acad. Sci. U. S. A.,1996

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The production, function, and clinical applications of IL-33 in type 2 inflammation-related respiratory diseases;Frontiers in Immunology;2024-09-05

2. Natural products for treating cytokine storm–related diseases: Therapeutic effects and mechanisms;Biomedicine & Pharmacotherapy;2023-11

3. The Correlation of Serum Calpain 1 Activity and Concentrations of Interleukin 33 in COVID-19 Acute Respiratory Distress Syndrome;Biomedicines;2023-06-27

4. Interesting effects of interleukins and immune cells on acute respiratory distress syndrome;Clinical and Experimental Medicine;2023-06-18

5. Jin-Zhen oral liquid for pediatric coronavirus disease (COVID-19): A randomly controlled, open-label, and non-inferiority trial at multiple clinical centers;Frontiers in Pharmacology;2023-02-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3